Royalty Pharma Accrued liabilities increased by 12.3% to $648.67M in Q1 2026 compared to the prior quarter. This increase may warrant attention — for this metric, lower values are generally preferred.
Significant increases may indicate rising long-term operational commitments or changes in accounting accrual estimates.
This represents long-term obligations that have been incurred but are not yet due for payment, excluding standard short-...
Varies significantly by industry; peers with similar service-based models often have comparable accrual structures.
other_accounts_payable_and_accrued_liabilities_noncurrent| Q4 '24 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|
| Value | $0.00 | $467.14M | $502.94M | $577.87M | $648.67M |
| QoQ Change | — | — | +7.7% | +14.9% | +12.3% |